The only currently available Food and Drug Administration-approved screening tests for prostate cancer result in a high number of false positives and lead to unnecessary biopsies and possible over-detection and over-treatment of indolent cancer, which never would have caused suffering or death.
PSA stands for prostate-specific antigen, a substance whose elevated levels can indicate prostate cancer but can also be caused by prostate inflammation or enlargement or other conditions. Its lack of specificity can result in unnecessary biopsies.
“This new test is more specific and accurate than the currently available blood tests for early prostate cancer detection,” said lead investigator William Catalona, MD, director of the clinical prostate cancer program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “This will focus on the detection of more life-threatening prostate cancers and reduce unnecessary biopsies in men 50 years of age and older.”
Catalona, known as the father of the PSA screening, was the first to show in 1991 that a simple blood test measuring PSA levels could be used to detect prostate cancer. He is a professor of urology at Northwestern University Feinberg School of Medicine and a urologist at Northwestern Memorial Hospital.
The study, which will be published in the May issue of the Journal of Urology, followed 900 patients from 10 sites, including Northwestern.
The results showed that the new screening test, a simple blood test called the Pro-PSA test, is particularly useful for patients with a normal prostate exam whose PSA is 2 to 10, a range considered the diagnostic gray zone because most men with higher levels have prostate cancer and most men with lower levels do not.
The Pro-PSA test measures a more specific PSA subform called (-2) Pro- PSA. The test becomes even more accurate when its results are analyzed with a mathematical formula that provides an overall Prostate Health Index. (The formula divides the Pro-PSA number by the free-PSA. Then the quotient of the two is multiplied by the square root of the total PSA. )
“The logic behind the formula is that the higher the Pro-PSA and the total PSA and the lower the free-PSA, the more likely the patient has aggressive prostate cancer,” Catalona said.
The new Pro-PSA test was recently approved for commercial use in Europe, Catalona noted.
“The FDA is currently reviewing our data from the study, and I’m hopeful that it will be approved in the United States as well,” he said.
Catalona conducted the study in collaboration with Beckman Coulter, Inc., a biomedical test developer and manufacturer, for which he serves as a paid consultant.
The trial was supported by Beckman Coulter. Catalona’s research also is supported by the National Cancer Institute and the Urological Research Foundation.
Members of the media, please contact Marla Paul via e-mail or at (312) 503-8928 for more information about this story.
[ PRESS RELEASE ]